BridgeBio Pharma Inc

Latest Results (03.04.2026):

BridgeBio Pharma Inc.'s financial report for the fourth quarter of 2025 (and full year 2025) shows commercial traction from Attruby driving Q4 net revenues of $154.2 million and full-year net revenues of $502.1 million, but the company remained unprofitable with a fourth-quarter net loss attributable to common stockholders of $192.9 million (full-year $724.9 million). Cash and marketable securities were $587.5 million at year-end (Dec 31, 2025), and BridgeBio closed a $632.5 million convertible notes issuance in January 2026 to support upcoming commercial launches and pipeline activities.

Revenues

Q4 2025 total revenues, net were $154.2M (Q4 Attruby net product revenue $146.0M). Full-year 2025 total revenues were $502.1M, primarily driven by Attruby product sales (full-year net product revenue $362.4M). The company reported 35% quarter-over-quarter net product revenue growth for Attruby in Q4.

Profitability (Loss) and EPS

BridgeBio reported a net loss attributable to common stockholders of $192.9M in Q4 2025 (vs. $265.1M in Q4 2024) and a full-year net loss of $724.9M (vs. $535.8M in 2024). Net loss per share was $1.00 for Q4 and $3.78 for the full year.

Operating Costs and Expense Drivers

Total operating costs were $293.7M in Q4 and $1.025B for 2025. SG&A rose sharply (Q4 SG&A $158.1M) reflecting commercial launch investments for Attruby; R&D decreased (Q4 R&D $116.4M) reflecting reprioritization after approvals. Stock‑based compensation for the year was $136.9M.

Other Income / Expense and Cash Flow

Total other expense, net was $(55.2)M in Q4 and $(209.1)M for 2025, driven by noncash interest on deferred royalty obligations and losses from equity method investments. Net cash used in operating activities for 2025 was $(445.9)M.

Balance Sheet and Financing

Cash, cash equivalents and marketable securities were $587.5M at December 31, 2025 (down from $681.1M a year earlier). In January 2026 the company completed issuance of $632.5M aggregate principal amount of convertible senior notes due 2033 to extend maturity and fund planned commercial and pipeline operations.

Commercial Momentum — Attruby

Attruby commercial performance: 7,804 unique patient prescriptions written by 1,856 unique prescribers (as of Feb 20, 2026). Attruby is presented as a differentiated TTR stabilizer (≥90% stabilization) and a key driver of product revenue growth in 2025.

Pipeline and Regulatory Milestones

BridgeBio reported three positive Phase 3 readouts recently and plans multiple NDA submissions in 2026: BBP‑418 (NDA planned 1H 2026), encaleret (NDA planned 1H 2026), and infigratinib (NDA planned 2H 2026). U.S. launches for BBP‑418 and encaleret are anticipated in late 2026/early 2027 if approved; infigratinib launch is planned for early‑mid 2027.